Stephens analyst Scott Fidel resumed coverage of Acadia Healthcare with an Equal Weight rating and $36 price target. He sees growth opportunities in the company's core U.S. behavioral business, but notes that U.S. same-store revenues growth has been trending lower and that the U.S. behavioral industry faces structural labor supply challenges. While Acadia has started to make progress on its U.K. operations, potential disruptions from the company's strategic review process and market pressures may slow more meaningful near-term improvements, Fidel added.